Voyager Therapeutics Inc.
www.voyagertherapeutics.com
Latest From Voyager Therapeutics Inc.
Axovant Closes Chapter On Failed, Second-Rate Small Molecule Strategy
Termination of nelotanserin, a small molecule licensed from Arena, in Lewy body dementias comes after a dramatic shift toward gene therapy.
Partnering In Cell And Gene Therapy Is A Unique Endeavor
Industry and academic representatives shared viewpoints at Biotech Week Boston in September 2018, including what is unique about deal-making in the cell and gene field.
Axovant Hopes Gene Silence Is Golden With Benitec Pact
Just over a month after inking a Parkinson's disease gene therapy pact with the UK's Oxford BioMedica, Axovant has licensed a 'silence-and-replace' technology from Australia's Benitec to tackle a rare but potentially fatal disease, oculopharyngeal muscular dystrophy.
Appointments: New CEOs For Lundbeck, Voyager & Neos, CSOs For iTeos & Tilos
Deborah Dunsire’s appointment to lead Lundbeck tops this week’s list of new hires; Astellas, Orchard Therapeutics, Voyager Therapeutics, iTeos Therapeutics, Cevec Pharmaceuticals, Sangamo Therapeutics, Cedilla Therapeutics, Tilos Therepautics and Neos Therapeutics have also appointed new executives and directors.
Company Information
- Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Synthesis Technologies, Production Processes
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
- Therapeutic Areas
- Neurology, Nervous System
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Company Type
- Start-Up
- Parent & Subsidiaries
- Voyager Therapeutics Inc.
- Senior Management
-
Andre Turenne, Pres. & CEO
Bernard Ravina, MD, CMO
Alison Dorval, VP, Fin.
Matthew P Ottmer, COO - Contact Info
-
Voyager Therapeutics Inc.
Phone: (857) 259-5340
75 Sidney St.
Cambridge, MA 02139
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice